Discontinued — last reported Q1 '18
Allowance for Doubtful Accounts Receivable (Current)
Gilead Sciences Allowance for Doubtful Accounts Receivable (Current) decreased by 18.0% to $41.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 36.9%, from $65.00M to $41.00M. Over 4 years (FY 2020 to FY 2024), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 4.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
Detailed definition
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Peer comparison
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $57.00M | $57.00M | $47.00M | $54.00M | $51.00M | $51.00M | $55.00M | $56.00M | $59.00M | $54.00M | $56.00M | $59.00M | $60.00M | $65.00M | $52.00M | $59.00M | $50.00M | $41.00M |
| QoQ Change | — | +0.0% | -17.5% | +14.9% | -5.6% | +0.0% | +7.8% | +1.8% | +5.4% | -8.5% | +3.7% | +5.4% | +1.7% | +8.3% | -20.0% | +13.5% | -15.3% | -18.0% |
| YoY Change | — | — | — | — | -10.5% | -10.5% | +17.0% | +3.7% | +15.7% | +5.9% | +1.8% | +5.4% | +1.7% | +20.4% | -7.1% | +0.0% | -16.7% | -36.9% |
Allowance for Doubtful Accounts Receivable (Current) at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's allowance for doubtful accounts receivable (current)?
- Gilead Sciences (GILD) reported allowance for doubtful accounts receivable (current) of $41.00M in Q3 2025.
- How has Gilead Sciences's allowance for doubtful accounts receivable (current) changed year-over-year?
- Gilead Sciences's allowance for doubtful accounts receivable (current) decreased by 36.9% year-over-year, from $65.00M to $41.00M.
- What is the long-term trend for Gilead Sciences's allowance for doubtful accounts receivable (current)?
- Over 4 years (2020 to 2024), Gilead Sciences's allowance for doubtful accounts receivable (current) has grown at a 4.3% compound annual growth rate (CAGR), from $44.00M to $52.00M.
- What does allowance for doubtful accounts receivable (current) mean?
- The estimated portion of customer invoices that the company expects will never be paid.